期刊文献+

CD44v6、ICAM-1及E-cadherin在子宫内膜异位症中的表达及意义 被引量:3

Expression and significance of CD44v6,ICAM-1 and E-cadherin in endometriosis
原文传递
导出
摘要 目的探讨黏附分子CD44异构体6(CD44v6)、细胞间黏附分子-1(ICAM-1)和细胞钙黏附素E(E-cadherin)在子宫内膜异位症(EMs)发生、发展中的作用。方法通过免疫组化方法分别检测CD44v6、ICAM-1和E-cadherin在子宫内膜异位症患者在位内膜、异位内膜和正常子宫内膜中的表达。结果 EMs患者中异位内膜CD44v6表达明显高于在位内膜和正常内膜(P<0.05);异位内膜中ICAM-1表达高于在位内膜(P<0.05),且其在位内膜高于正常内膜(P<0.05);异位内膜及在位内膜中E-cadherin表达显著低于正常内膜(P<0.05)。结论子宫内膜异位症异位内膜、在位内膜中CD44v6、ICAM-1的高表达和E-cadherin的低表达在子宫内膜异位症的发生、发展中起重要作用。 Objective To investigate the role of CD44v6,ICAM-1 and E-cadherin in development of endmetriosis(EMs).Methods Immunohistochemical method was used to detect the expression of CD44v6,ICAM-1 and E-cadherin in the EMs eutopic,ectopic endometrium and normal endometrium.Results CD44v6 expression in ectopic endometrium was significantly higher than that in the eutopic endometrium and the normal endometrium(P0.05).ICAM-1 expression in the ectopic endometrium was higher than that in the eutopic endometrium,and ICAM-1 expression in the eutopic endometrium was higher than that in the normal endometrium(P0.05).E-cadherin expression in the ectopic endometrium and the eutopic endometrium decreased significantly than that in the normal endometrium(P0.05).Conclusion Higher expression of CD44v6 and ICAM-1 and lower expression of E-cadherin in ectopic and eutopic endometrium of EMs play an important role in the development of EMs.
出处 《临床医学》 CAS 2013年第1期4-6,F0003,共4页 Clinical Medicine
  • 相关文献

参考文献4

二级参考文献37

  • 1罗锦辉,唐建武.PDGF-B、PDGFR-α在小细胞肺癌中的不同表达[J].肿瘤,2004,24(5):476-477. 被引量:12
  • 2PARKIN D M,BRAY F,FERLAY J,et al.Global cancer statistics,2002[J].CA-Cancer J Clin,2005,55(2):74-108.
  • 3SCHNEIDER S,YOCHIM J,BRABENDER J,et al.Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer[J].Clin Cancer Res,2004,10(5):1588-1596.
  • 4MIYOSHI T,KONDO K,HINO N,et al.The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer[J].Clin Cancer Res,1997,3(8):1289-1297.
  • 5SHIJUBO N,UEDE T,KON S,et al.Vascular endothelial growth factor and osteopontin in stage 1 lung adenocarcinoma[J].Am J Respir Crit Care Med,1999,160:1269-1273.
  • 6BROWN L F,PAPADOPOULOS S A,BERSE B,et al.Osteopontin expression and distribution in human carcinomas[J].Am J Pathol,1994,145:610-623.
  • 7ZHANG J,TAKAHASHI K,TAKAHASHI F,et al.Differential osteopontin expression in lung cancer[J].Cancer Let,2001,171:215-222.
  • 8AGRAWAL D,CHEN T,IRBY R,et al.Osteopontin identified as lead marker of colon cancer progression,using pooled sample expression profiling[J].J Natl Cancer Inst,2002,94:513-521.
  • 9DENHARDT DT,GIACHELLI C M,RITTLING SR.Role of osteopontin in cellular signaling and toxicant injury[J].Annu Rev Pharmacol Toxicol,2001,41:723-749.
  • 10KATAGIRI Y U,SLEEMAN J,FUJII H,et al.CD44 variants but not CD44s cooperate with b1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycineaspartic acid,thereby stimulating cell motility and chemotaxis[J].Cancer Res,1999,59:219-226.

共引文献292

同被引文献64

引证文献3

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部